The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

German family-owned pharma major Boehringer Ingelheim and Denmark’s LEO Pharma today announced an exclusive global license ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Boehringer Ingelheim’s Spevigo (spesolimab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat generalised pustular psoriasis (GPP) flares. The health ...

Spesolimab (Spevigo) is available on the NHS as a possible treatment for generalised pustular psoriasis (GPP) flares in adults. It should only be used to treat: moderate to severe flares that have not ...

Spevigo, a lifesaving rare-disease therapy that won the Prix Galien — the Nobel Prize of drug development — was developed right here in Ridgefield.

Two new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish Medicines Consortium (SMC) announced it had recommended two treatments for the diseases.

SPEVIGO ® is a novel, humanized, selective antibody that specifically blocks the activation of the IL-36R, a signaling pathway within the immune system shown to be involved in the pathogenesis of ...